Literature DB >> 16014115

Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance.

A Ayhan1, D Ertunc, E C Tok, A Ayhan1.   

Abstract

The purpose of this study was to evaluate the prognostic significance of c-Met expression in advanced cases of epithelial ovarian carcinoma. Paraffin-embedded tissues from 41 stage IIIC primary ovarian adenocarcinoma were stained immunohistochemically for c-Met expression. The expression of c-Met was correlated with conventional clinicopathologic parameters and with overall survival of the patients. c-Met expression was found in 60.9% of cases. This clinicopathologic study showed that epithelial ovarian carcinomas with c-Met expression had higher histologic tumor grade and were more frequently associated with para-aortic lymph node metastasis (P < 0.05). In multivariate analysis, c-Met expression remained as a statistically significant predictor for survival with histologic grade. The patients with stage IIIC epithelial ovarian cancers whose tumors expressed c-Met were more likely to have high-grade tumors, have more para-aortic lymph node involvement, and have a significantly worse overall survival than those whose tumors were c-Met negative. In conclusion, c-Met expression might be a potential prognostic marker for patients with advanced-stage epithelial ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014115     DOI: 10.1111/j.1525-1438.2005.00117.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  22 in total

1.  Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo.

Authors:  Xiao-lei Wang; Xi-mei Chen; Jian-ping Fang; Chang-qin Yang
Journal:  Acta Pharmacol Sin       Date:  2012-03-12       Impact factor: 6.150

2.  Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.

Authors:  Ana M Gonzalez-Angulo; Huiqin Chen; Meghan S Karuturi; Mariana Chavez-MacGregor; Spyrus Tsavachidis; Funda Meric-Bernstam; Kim-Anh Do; Gabriel N Hortobagyi; Patricia A Thompson; Gordon B Mills; Melissa L Bondy; George R Blumenschein
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

3.  Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.

Authors:  Chuanhui Xu; Wouter Plattel; Anke van den Berg; Nele Rüther; Xin Huang; Miao Wang; Debora de Jong; Hans Vos; Gustaaf van Imhoff; Andreas Viardot; Peter Möller; Sibrand Poppema; Arjan Diepstra; Lydia Visser
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 4.  Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer.

Authors:  Youngjoo Kwon; Andrew K Godwin
Journal:  Reprod Sci       Date:  2016-09-27       Impact factor: 3.060

5.  Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.

Authors:  Xiao-Xiu Huang; Feng-Feng Xie; Li-Jiao Hou; Xiu-Xiu Chen; Rong-Ying Ou; Jiang-Tao Yu; Jian-Ge Qiu; Wen-Ji Zhang; Qi-Wei Jiang; Yang Yang; Di-Wei Zheng; Yao Chen; Jia-Rong Huang; Kun Wang; Meng-Ning Wei; Wen-Feng Li; Zhi Shi; Xiao-Jian Yan
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

6.  Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.

Authors:  Kelong Han; Pascal Chanu; Fredrik Jonsson; Helen Winter; René Bruno; Jin Jin; Mark Stroh
Journal:  AAPS J       Date:  2016-12-27       Impact factor: 4.009

7.  Assessment of hepatocyte growth factor in ovarian cancer mortality.

Authors:  Ellen L Goode; Georgia Chenevix-Trench; Lynn C Hartmann; Brooke L Fridley; Kimberly R Kalli; Robert A Vierkant; Melissa C Larson; Kristin L White; Gary L Keeney; Trynda N Oberg; Julie M Cunningham; Jonathan Beesley; Sharon E Johnatty; Xiaoqing Chen; Katelyn E Goodman; Sebastian M Armasu; David N Rider; Hugues Sicotte; Michele M Schmidt; Elaine A Elliott; Estrid Høgdall; Susanne Krüger Kjær; Peter A Fasching; Arif B Ekici; Diether Lambrechts; Evelyn Despierre; Claus Høgdall; Lene Lundvall; Beth Y Karlan; Jenny Gross; Robert Brown; Jeremy Chien; David J Duggan; Ya-Yu Tsai; Catherine M Phelan; Linda E Kelemen; Prema P Peethambaram; Joellen M Schildkraut; Vijayalakshmi Shridhar; Rebecca Sutphen; Fergus J Couch; Thomas A Sellers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-01       Impact factor: 4.254

Review 8.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

Review 9.  The tumor microenvironment and metastatic disease.

Authors:  Sarah Jane Lunt; Naz Chaudary; Richard P Hill
Journal:  Clin Exp Metastasis       Date:  2008-06-10       Impact factor: 5.150

10.  An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.

Authors:  Marion Zillhardt; James G Christensen; Ernst Lengyel
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.